Rocket Pharmaceuticals Inc.
RCKT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RCKT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RCKT
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company developing gene therapies for rare, monogenic diseases, with a focus on cardiovascular indications and a pipeline including RP-L102 for Fanconi Anemia and RP-L301 for Pyruvate Kinase Deficiency.
Key risk: No approved products or revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 13 clinical trials for Rocket Pharmaceuticals Inc..
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company developing gene therapies for rare, monogenic diseases, with a focus on cardiovascular indications and a pipeline including RP-L102 for Fanconi Anemia and RP-L301 for Pyruvate Kinase Deficiency.
- Rocket Pharmaceuticals is advancing clinical programs for rare diseases, including RP-L102 for Fanconi Anemia (FA) and RP-L301 for Pyruvate Kinase Deficiency (PKD), with regulatory interactions ongoing [sec · filed 2025-04-30].
- The company operates a ~100,000 sq. ft. in-house AAV cGMP manufacturing facility in Cranbury, New Jersey to support clinical and future commercial endeavors [sec · filed 2026-04-06].
- As of June 30, 2026, the company reported cash & equivalents of $225.8M, no revenue, net income of $123.2M (driven by a $178.2M priority review voucher sale), shareholders' equity of $277.2M, and total debt of $19.3M [sec].
- Rocket has incurred net losses since inception, with an accumulated deficit of $1.44 billion as of December 31, 2025, and net losses of $223.1M and $258.7M for fiscal years 2025 and 2024, respectively [sec_mda · as of 2026-02-26].
- The company's near-term research focus is on rare cardiovascular gene therapies targeting genetically defined cardiomyopathies, which impact over 100,000 patients in the U.S. and EU [sec_mda · as of 2026-02-26].
What works
- Rocket has a late-stage pipeline with regulatory submissions underway, including EMA acceptance of a marketing authorization application for RP-L102 for Fanconi Anemia [sec · filed 2025-04-30].
- The company operates an in-house AAV cGMP manufacturing facility, providing internal capacity for clinical and potential commercial production [sec · filed 2026-04-06].
- Management has a proven track record of over 20 successful U.S. and international drug approvals and launches in cell and gene therapies and rare diseases [sec · filed 2026-04-06].
- The company generated significant non-dilutive income through the sale of a priority review voucher for $178.2 million in the first half of 2026, bolstering its cash position [sec_mda · as of 2026-08-10].
What to weigh
- Rocket has no approved products and has not generated any revenue from product sales since inception, relying on external financing and non-dilutive sources to fund operations [sec_mda · as of 2026-02-26].
- The company has a history of significant operating losses, with an accumulated deficit of $1.44 billion as of December 31, 2025, and negative cash flows from operations [sec_mda · as of 2026-02-26].
- Enrollment for the Phase 2 pivotal trial of RP-L301 for PKD has not been initiated, as the company is prioritizing other programs, indicating potential delays or resource constraints [sec · filed 2025-04-30].
- The company's future capital requirements are uncertain and depend on the success of clinical trials, regulatory approvals, and potential collaborations, with R&D expenses expected to increase [sec_mda · as of 2026-02-26].
From the filings
Quoted directly from source documents.
Rocket has no approved products and has not generated revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · February 26, 2026
The company sold a priority review voucher for $178.2 million in the first half of 2026.
“The increase in other income was primarily driven by the sale of the PRV for net $178.2 million.”
SEC MD&A · August 10, 2026
Rocket has an accumulated deficit of $1.44 billion as of December 31, 2025.
“have an accumulated deficit of $1.44 billion as of December 31, 2025.”
SEC MD&A · February 26, 2026
The company's near-term research focus is on rare cardiovascular gene therapies.
“Strategic Focus on Rare Cardiovascular Indications: Our near-term research and platform investments are focused on leveraging our AAV capabilities in rare cardiovascular diseases.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2020-07-06 · Phase 1 Start: Gene Therapy for Pyruvate Kinase Deficiency (PKD) — A Phase I clinical trial evaluating safety of RP-L301 for PKD has been completed.
- 2020-07-15 · Phase 2 Start: A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced — A Phase 2 trial for RP-L102 is active but not recruiting, assessing bone marrow colony-forming cell resistance.
- 2023-08-29 · Phase 1 Start: A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associate — A Phase 1 dose escalation trial for an AAV gene therapy is currently recruiting participants.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has never generated product revenue, relying on external funding [sec_mda · as of 2026-02-26].
- Significant accumulated deficit — Accumulated deficit of $1.44 billion as of December 31, 2025, with ongoing net losses and negative cash flows [sec_mda · as of 2026-02-26].
- Clinical trial delays or failures — Enrollment for the Phase 2 RP-L301 trial has not started due to resource prioritization, risking program timelines [sec · filed 2025-04-30].
- Dependence on additional financing — Future capital requirements are uncertain and the company expects R&D expenses to increase, requiring further funding [sec_mda · as of 2026-02-26].
What to watch
- Regulatory decisions on the marketing authorization application for RP-L102 for Fanconi Anemia, accepted by the EMA [sec · filed 2025-04-30].
- Initiation of enrollment in the Phase 2 pivotal trial for RP-L301 for Pyruvate Kinase Deficiency, which has not yet started [sec · filed 2025-04-30].
- Progress of the Phase 1 dose escalation trial for an intravenously administered AAV gene therapy (NCT05885412), which is currently recruiting [catalyst].
- Cash runway and potential need for additional financing, given the accumulated deficit and lack of product revenue [sec_mda · as of 2026-02-26].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Rocket Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rocket Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
21.5 months
D/E 0.15 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 14 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$350.5M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 17,687,772 | $63.3M |
| blackrock, inc. | 7,834,795 | $28.0M |
| vanguard capital management llc | 7,551,472 | $27.0M |
| citigroup inc | 5,107,708 | $18.3M |
| vanguard portfolio management llc | 4,690,215 | $16.8M |
| state street corp | 4,485,989 | $16.1M |
| maverick capital ltd | 3,567,372 | $12.8M |
| newtyn management, llc | 3,165,900 | $11.3M |
| millennium management llc | 3,118,124 | $11.2M |
| aqr capital management llc | 3,069,930 | $11.0M |
Showing top 10 of 196 institutional holders of Rocket Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 24.2%
- Days to cover
- 7.9
- Shares short
- 21,549,583
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RCKT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rocket Pharmaceuticals Inc.?
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company developing gene therapies for rare, monogenic diseases, with a focus on cardiovascular indications and a pipeline including RP-L102 for Fanconi Anemia and RP-L301 for Pyruvate Kinase Deficiency.
Who is the CEO of Rocket Pharmaceuticals Inc.?
Dr. Gaurav D. Shah M.D. is the chief executive officer of Rocket Pharmaceuticals Inc. (RCKT).
Where is Rocket Pharmaceuticals Inc. headquartered?
Rocket Pharmaceuticals Inc. (RCKT) is headquartered in Cranbury, NJ, United States.
What therapeutic areas does Rocket Pharmaceuticals Inc. focus on?
Rocket Pharmaceuticals Inc. develops therapies across Rare Disease, Gene Therapy, Cardiovascular, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.